This section provides an overview of Failed Alzheimer's Disease Clinical Trials Analysis. Additional content will be added here.
Failed Alzheimer'S Disease Clinical Trials Analysis is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Over 200 Alzheimer's disease clinical trials have failed over the past two decades. This page systematically analyzes these failures to identify patterns and extract actionable lessons for future therapeutic development.
| Trial | Drug | Year | Why It Failed | Lessons |
|---|---|---|---|---|
| EPOCH | Verubecestat | 2017 | Cognitive worsening, synaptic loss[1] | Off-target effects on synaptic proteins |
| MISSION-AD1 | Atabecestat | 2018 | Cognitive decline, liver toxicity | BACE1 inhibition too broad |
| EANCEPT | Elenbecestat | 2019 | Cognitive worsening | Similar off-target issues |
Failure Scores:
Key Lesson: BACE inhibition reduces Aβ but causes synaptic dysfunction. Need pathway modulation, not complete blockade.
| Trial | Drug | Year | Why It Failed | Lessons |
|---|---|---|---|---|
| IDENTITY | Semagacestat | 2010 | Worse cognition, skin cancer, Notch toxicity[2] | Gamma-secretase has 100+ substrates |
| APOLLOE4 | Avagacestat | 2012 | Cognitive worsening, GI toxicity | Notch-sparing approach failed |
Failure Scores:
Key Lesson: Broad-spectrum enzyme inhibition causes off-target toxicity. Need selective modulation.
| Trial | Drug | Year | Why It Failed | Lessons |
|---|---|---|---|---|
| AN-1792 | Accumbens | 2003 | Meningoencephalitis (6% death)[3] | Autoimmune response to Aβ |
| ACC-001 | CAD106 | 2015 | Tolerability issues | Better safety but limited efficacy |
Failure Scores:
Key Lesson: Active vaccination causes dangerous autoimmune response. Passive antibodies are safer.
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| EXPEDITION 1/2/3 | Solanezumab | 2012-2016 | No cognitive benefit[4] | Targeted monomeric Aβ, not toxic species |
| DIAN-TU | Solanezumab | 2020 | Failed in prevention | Wrong Aβ species |
Failure Scores:
Key Lesson: Must target the right toxic Aβ species (oligomers, protofibrils), not monomers.
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| GRADUATE 1/2 | Gantenerumab | 2012-2022 | Initially failed, then positive in high-dose[5] | Initial doses too low |
Re-analysis Scores:
Key Lesson: Start with high doses in initial trials; don't undertreat for safety.
| Trial | Drug | Years | Why It Failed (initially) | Lessons |
|---|---|---|---|---|
| EMERGE | Aducanumab | 2019 | Positive (high dose) | — |
| ENGAGE | Aducanumab | 2019 | Negative (some patients had high exposure) | Dose exposure mattered |
Analysis Scores:
Key Lesson: High-dose, continuous treatment essential; adaptive designs needed.
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| CONCERT | Dimebolin | 2013 | No cognitive benefit | Mechanism unclear |
Failure Scores:
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| LIGHT | Azeliragon | 2019 | No benefit, some toxicity[6] | RAGE not central in AD |
Failure Scores:
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| TAURIEL | LMTM (TRx0237) | 2017-2019 | Failed primary endpoint[7] | Monotherapy failed, some post-hoc benefit |
Failure Scores:
Key Lesson: Tau inhibitors may need combination with anti-amyloid.
| Pattern | Example | Frequency |
|---|---|---|
| Wrong Aβ species | Solanezumab → monomers | Common |
| Wrong pathway | RAGE inhibitors | Occasional |
| Symptomatic only | Dimebolin | Occasional |
| Pattern | Example | Frequency |
|---|---|---|
| Poor brain penetration | Early antibodies | Rare now |
| Insufficient dosing | Early gantenerumab | Occasional |
| Pattern | Example | Frequency |
|---|---|---|
| Off-target toxicity | BACE, gamma-secretase | Common |
| Autoimmunity | AN-1792 vaccine | Rare |
| Excessive caution | Underdosing | Common |
| Pattern | Example | Frequency |
|---|---|---|
| Too advanced | Most late-stage trials | Very common |
| Mixed pathology | Including non-AD | Common |
| Biomarker-negative | No amyloid | Occasional |
Based on failure analysis, the following approaches have highest probability of success:
Why they work: Learn from solanezumab (wrong target), gantenerumab (underdosing), BACE (off-target)
Why it works: Single targets have 27% ceiling; combinations address multiple pathways
The study of Failed Alzheimer'S Disease Clinical Trials Analysis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Additional resources and databases will be listed here.
Related pages will be listed here.
Egan MF, Kost J, Tariot PN, et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine. 2018;378(18):1691-1703. ↩︎
Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine. 2013;369(4):341-350. ↩︎
Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46-54. ↩︎
Honig LS, Vellas B, Woodward M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. New England Journal of Medicine. 2018;378(4):321-330. ↩︎
Bateman RJ, Smith J, Donohue MC, et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;389(18):1692-1704. ↩︎
Galasko DR, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 2014;82(17):1536-1542. ↩︎
Wilcock GK, Gauthier S, Frisoni GB, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2018;388(10062):2873-2884. ↩︎
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388(1):9-21. ↩︎